Analysis Offers Insight into Patients Most Likely to Derive Benefit from Tofacitinib
An analysis of the ORAL Surveillance trial details the efficacy of tofacitinib relative to TNF inhibition based on history of ASCVD and baseline cardiovascular risk.
Source: hcplive.com